Skip to content

Study · Not a test of the peptide alone · 2020

3 results

Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective.

Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY

Seminars in arthritis and rheumatism13 Feb 2020Cited by 20 (Europe PMC)

PMID32160943 (opens in a new tab)DOI10.1016/j.semarthrit.2020.02.004 (opens in a new tab)PepBankPUB-32160943
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

ObjectivesEmerging evidence supports sequential therapy with anabolic followed by antiresorptive in patients at high-risk of fragility fractures. This study assessed the cost-effectiveness of sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) [(ABL/ALN)] compared to ALN monotherapy and to sequential treatment starting with antiresorptive therapy (ALN/ABL/ALN).MethodsA previously validated Markov microsimulation model was used to estimate the cost-effectiveness of sequential ABL/ALN compared to ALN monotherapy and to sequential ALN/ABL/ALN from a lifetime US payer perspective. In line with practice guidelines, patients were assumed to receive ABL for 18 months followed by 5 years of ALN, or ALN monotherapy for 5 years, or a sequence of ALN for 2 years followed by 18 months of ABL and then by 3 years ALN. Evaluation was conducted for patients aged 50-80 years old with a BMD T-score ≤-3.5 and without a history of prior fracture, or with a T-score between -2.5 and -3.5 and a history of ≥ 1 osteoporotic fracture.ResultsSequential ABL/ALN was cost-effective (threshold of US$150,000 per QALY) vs generic ALN monotherapy in women ≥60 years with a BMD T-score ≤-3.5 and in women with BMD T-score between -2.5 and -3.5 and history of osteoporotic fracture. In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, more QALYs) compared with sequential ALN/ABL/ALN, resulting from limited effect of ABL in patients previously treated with an antiresorptive agent.ConclusionsSequential ABL/ALN therapy is cost-effective vs ALN monotherapy for US postmenopausal women aged ≥60 years at increased risk of fractures.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther

    In simulated women at increased fracture risk, sequential abaloparatide/alendronate was cost-effective versus alendronate in the stated age and fracture-risk strata.

    In plain wordsA computer simulation estimated that sequential abaloparatide/alendronate was cost-effective versus alendronate in specified simulated populations.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableCost-effectiveness versus alendronate
    Study

    n: not reported in source

    Markov microsimulation
    Comparator
    alendronate monotherapy
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Sequential ABL/ALN was cost-effective (threshold of US$150,000 per QALY) vs generic ALN monotherapy in women ≥60 years with a BMD T-score ≤-3.5 and in women with BMD T-score between -2.5 and -3.5 and history of osteoporotic fracture.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was used to estimate the cost-effectiveness of sequential ABL/ALN compared to ALN monotherapy and to sequential ALN/ABL/ALN from a lifetime US payer perspective.
    Summary · context
    Evaluation was conducted for patients aged 50-80 years old with a BMD T-score ≤-3.5 and without a history of prior fracture, or with a T-score between -2.5 and -3.5 and a history of ≥ 1 osteoporotic fracture.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther

    In all simulated populations, sequential abaloparatide/alendronate had lower costs than alendronate/abaloparatide/alendronate.

    In plain wordsA computer model found lower costs with abaloparatide/alendronate than with alendronate/abaloparatide/alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseLifetime costs
    Study

    n: not reported in source

    Markov microsimulation
    Comparator
    alendronate/abaloparatide/alendronate
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, more QALYs) compared with sequential ALN/ABL/ALN, resulting from limited effect of ABL in patients previously treated with an antiresorptive agent.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was used to estimate the cost-effectiveness of sequential ABL/ALN compared to ALN monotherapy and to sequential ALN/ABL/ALN from a lifetime US payer perspective.
    Summary · context
    Evaluation was conducted for patients aged 50-80 years old with a BMD T-score ≤-3.5 and without a history of prior fracture, or with a T-score between -2.5 and -3.5 and a history of ≥ 1 osteoporotic fracture.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 03Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther

    In all simulated populations, sequential abaloparatide/alendronate produced more QALYs than alendronate/abaloparatide/alendronate.

    In plain wordsA computer model found more quality-adjusted life years with abaloparatide/alendronate than with alendronate/abaloparatide/alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseQuality-adjusted life years
    Study

    n: not reported in source

    Markov microsimulation
    Comparator
    alendronate/abaloparatide/alendronate
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    In all simulated populations, sequential ABL/ALN therapy was dominant (lower costs, more QALYs) compared with sequential ALN/ABL/ALN, resulting from limited effect of ABL in patients previously treated with an antiresorptive agent.
    2 context sentences
    Summary · context
    A previously validated Markov microsimulation model was used to estimate the cost-effectiveness of sequential ABL/ALN compared to ALN monotherapy and to sequential ALN/ABL/ALN from a lifetime US payer perspective.
    Summary · context
    Evaluation was conducted for patients aged 50-80 years old with a BMD T-score ≤-3.5 and without a history of prior fracture, or with a T-score between -2.5 and -3.5 and a history of ≥ 1 osteoporotic fracture.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.